Latest news and articles about أدوية السمنة from NEX English
India is witnessing a significant rise in cheap copies of the drug 'semaglutide', negatively affecting sales for Eli Lilly. This situation raises questions about the company's future as patent expirations approach.
A recent study has revealed that specific genes play a crucial role in the success of weight loss injections like Wegovy and Mounjaro, with varying results and side effects among individuals. This highlights the importance of genetic factors in weight management treatments.
Novo Nordisk has announced the launch of a new high-dose GLP-1 injection for obesity treatment, priced $50 lower than its competitor Zepbound. This release comes amid increasing competition in the obesity medication market.
Reports indicate that Nirokrin is nearing a deal to acquire Soleno Therapeutics, potentially enhancing its efforts to develop new obesity treatments. This announcement comes amid significant changes in the pharmaceutical market.
Eli Lilly has announced the launch of a new weight loss medication called <strong>Foundayo</strong>, which can be taken once daily at any time. This drug is considered a major competitor to <strong>Wegovy</strong> in the weight loss market.
Innovent Biologics has announced its first-ever profits, showcasing the success of its strategies in the obesity drug market. This comes as the company faces increasing competition from generic weight loss medications in China.
Novo Nordisk announced that Wegovy pills demonstrated superior weight loss results compared to Eli Lilly's Foundayo pills. This highlights the competitive landscape of obesity medications.
Kailera Therapeutics has announced its application for an initial public offering (IPO) in the United States to raise funds for developing a range of obesity treatments. This move comes as the global demand for effective solutions to combat the obesity crisis continues to rise.